Relumina tablets 40 mg for uterine myoma (Relugolix)
What are Relumina tablets 40 mg for uterine myoma (Relugolix)?
Relumina tablets contain relugolix, a gonadotropin-releasing hormone antagonist. By inhibiting the secretion of luteinizing hormone, follicle-stimulating hormone, and progesterone, these tablets play an important role in regulating the hormonal balance within the body.
The primary objective of Relumina tablets is to reduce sex hormone levels, particularly progesterone and estradiol, within the ovaries. This hormone reduction aids in addressing various health conditions and symptoms related to hormonal imbalances. One of the significant medical applications of Relumina tablets is in the treatment of uterine myomas, also known as uterine fibroids. These noncancerous growths within the uterus can lead to complications like menorrhagia (excessive menstrual bleeding) and low back pain, causing considerable discomfort for affected individuals. Clinical trials involving Relumina's active component, relugolix, have exhibited impressive results in managing heavy menstrual bleeding caused by uterine fibroids. When compared to a placebo, relugolix combinations demonstrated a substantially higher response rate of 73.4% in effectively treating this condition.
Moreover, beyond alleviating heavy menstrual bleeding, Relumina tablets have shown considerable promise in addressing the associated pain. In clinical studies, a statistically significant reduction in pain was observed in 57.6% of women treated with relugolix, while only 3.1% of women receiving a placebo reported similar pain relief.
Active principles: relugolix
Amount: 100 tablets
Maker: ASKA Pharmaceutical Co. Ltd., Tokyo, Japan
Indications: treatment of uterine myoma (uterine fiboids) and the following symptoms:
- lower abdominal pain,
- low back pain
How to take
Adults should take 1 tablet (40 mg of the active principle) at a time, once a day, before meal. The first dose should be taken from first to fifth day of menstrual cycle.
Contraindications: do not use for pregnant, possibly pregnant or breastfeeding women. Do not use for patients with submucosal myoma or undiagnosed abnormality in genital bleeding.
Patient should take an adequate contraception to avoid pregnancy during taking this medicine, using the method other than hormonal contraception.
The usual treatment duration is within 6 months. If upon your doctor's decision you should take the medicine for more than 6 months, you should be tested for bone mineral density regularly and pay attention to estrogen lowering effect.
If an allergic reaction occurs, patient needs to stop using the medicine and consult with their doctor. If patient is taking any other medication or treatment, they should consult with their doctor in advance.